-
1
-
-
0037421584
-
Inheritance and drug response
-
DOI 10.1056/NEJMra020021
-
R Weinshilboum 2003 Inheritance and drug response N Engl J Med 48 529 537 10.1056/NEJMra020021 (Pubitemid 36159889)
-
(2003)
New England Journal of Medicine
, vol.348
, Issue.6
, pp. 529-537
-
-
Weinshilboum, R.1
-
2
-
-
0032569831
-
Tamoxifen in the treatment of breast cancer
-
DOI 10.1056/NEJM199811263392207
-
CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618 10.1056/NEJM199811263392207 1:CAS:528:DyaK1cXnvFOitLs%3D 9828250 (Pubitemid 28536137)
-
(1998)
New England Journal of Medicine
, vol.339
, Issue.22
, pp. 1609-1618
-
-
Osborne, C.K.1
-
3
-
-
19344364880
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
4
-
-
0035795683
-
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
-
10.1093/jnci/93.9.684 1:CAS:528:DC%2BD3MXjvVamu70%3D 11333290
-
B Fisher J Dignam J Bryant N Wolmark 2001 Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial J Natl Cancer Inst 93 684 690 10.1093/jnci/93.9.684 1:CAS:528:DC%2BD3MXjvVamu70%3D 11333290
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 684-690
-
-
Fisher, B.1
Dignam, J.2
Bryant, J.3
Wolmark, N.4
-
5
-
-
0035925617
-
Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years
-
10.1093/jnci/93.6.456 1:CAS:528:DC%2BD3MXislCrtLk%3D 11259471
-
HJ Stewart RJ Prescott AP Forrest 2001 Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years J Natl Cancer Inst 93 456 462 10.1093/jnci/93.6.456 1:CAS:528:DC%2BD3MXislCrtLk%3D 11259471
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 456-462
-
-
Stewart, H.J.1
Prescott, R.J.2
Forrest, A.P.3
-
6
-
-
33847373003
-
Early discontinuation of tamoxifen: A lesson for oncologists
-
DOI 10.1002/cncr.22485
-
TI Barron R Connolly K Bennett, et al. 2007 Early discontinuation of tamoxifen: a lesson for oncologists Cancer 109 832 839 10.1002/cncr.22485 1:CAS:528:DC%2BD2sXjsVKns7s%3D 17243168 (Pubitemid 46333524)
-
(2007)
Cancer
, vol.109
, Issue.5
, pp. 832-839
-
-
Barron, T.I.1
Connolly, R.M.2
Bennett, K.3
Feely, J.4
Kennedy, M.J.5
-
7
-
-
0035863386
-
Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women
-
1:CAS:528:DC%2BD3MXhtVektrk%3D 11208822
-
S Demissie RA Silliman TL Lash 2001 Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women J Clin Oncol 19 322 328 1:CAS:528:DC%2BD3MXhtVektrk%3D 11208822
-
(2001)
J Clin Oncol
, vol.19
, pp. 322-328
-
-
Demissie, S.1
Silliman, R.A.2
Lash, T.L.3
-
9
-
-
4243063941
-
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
-
DOI 10.1124/jpet.104.065607
-
Z Desta BA Ward NV Soukhova, et al. 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062 1075 10.1124/jpet.104.065607 1:CAS:528:DC%2BD2cXnt1eqtb0%3D 15159443 (Pubitemid 39108928)
-
(2004)
Journal of Pharmacology and Experimental Therapeutics
, vol.310
, Issue.3
, pp. 1062-1075
-
-
Desta, Z.1
Ward, B.A.2
Soukhova, N.V.3
Flockhart, D.A.4
-
10
-
-
19944434201
-
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
-
1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 15632378
-
Y Jin Z Desta V Stearns, et al. 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 15632378
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 30-39
-
-
Jin, Y.1
Desta, Z.2
Stearns, V.3
-
11
-
-
0017665570
-
A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity
-
10.1677/joe.0.0750305 1:CAS:528:DyaE1cXmvFCrtQ%3D%3D 591813
-
VC Jordan MM Collins L Rowsby G Prestwich 1977 A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity J Endocrinol 75 305 316 10.1677/joe.0.0750305 1:CAS:528:DyaE1cXmvFCrtQ%3D%3D 591813
-
(1977)
J Endocrinol
, vol.75
, pp. 305-316
-
-
Jordan, V.C.1
Collins, M.M.2
Rowsby, L.3
Prestwich, G.4
-
12
-
-
0021732038
-
Inhibition of estradiol-induced growth of cultured human breast cancer cells by the anti-estrogens tamoxifen, desmethyl-tamoxifen, 4-hydroxy-tamoxifen and enclomiphene
-
DOI 10.1016/0006-2952(84)90007-8
-
C Marth G Daxenbichler GC Buehring, et al. 1984 Inhibition of the estradiol-induced growth of cultured human breast cancer cells by the anti-estrogens tamoxifen, desmethyl-tamoxifen, 4-hydroxy-tamoxifen and enclomiphene Biochem Pharmacol 33 3951 3956 10.1016/0006-2952(84)90007-8 1:CAS:528:DyaL2MXls1enug%3D%3D 6439216 (Pubitemid 15135025)
-
(1984)
Biochemical Pharmacology
, vol.33
, Issue.24
, pp. 3951-3956
-
-
Marth, C.1
Daxenbichler, G.2
Buehring, G.C.3
-
13
-
-
0037094334
-
Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases
-
DOI 10.1016/S0006-2952(02)00994-2, PII S0006295202009942
-
T Nishiyama K Ogura H Nakano, et al. 2002 Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases Biochem Pharmacol 63 1817 1830 10.1016/S0006-2952(02)00994-2 1:CAS:528:DC%2BD38XktVCit7c%3D 12034366 (Pubitemid 34603446)
-
(2002)
Biochemical Pharmacology
, vol.63
, Issue.10
, pp. 1817-1830
-
-
Nishiyama, T.1
Ogura, K.2
Nakano, H.3
Ohnuma, T.4
Kaku, T.5
Hiratsuka, A.6
Muro, K.7
Watabe, T.8
-
14
-
-
0023922814
-
Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile
-
1:CAS:528:DyaL1cXktVSqurk%3D 3349495
-
EA Lien E Solheim S Kvinnsland PM Ueland 1988 Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile Cancer Res 48 2304 2308 1:CAS:528:DyaL1cXktVSqurk%3D 3349495
-
(1988)
Cancer Res
, vol.48
, pp. 2304-2308
-
-
Lien, E.A.1
Solheim, E.2
Kvinnsland, S.3
Ueland, P.M.4
-
15
-
-
0346602691
-
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
-
1:CAS:528:DC%2BD3sXpvVelsbc%3D 14652237
-
V Stearns MD Johnson JM Rae, et al. 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 1758 1764 1:CAS:528:DC%2BD3sXpvVelsbc%3D 14652237
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 1758-1764
-
-
Stearns, V.1
Johnson, M.D.2
Rae, J.M.3
-
16
-
-
0026585136
-
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer
-
10.2165/00003088-199222050-00002 1:STN:280:DyaK38zntVyltQ%3D%3D 1505141
-
PE Lonning EA Lien S Lundgren S Kvinnsland 1992 Clinical pharmacokinetics of endocrine agents used in advanced breast cancer Clin Pharmacokinet 22 327 358 10.2165/00003088-199222050-00002 1:STN:280:DyaK38zntVyltQ%3D%3D 1505141
-
(1992)
Clin Pharmacokinet
, vol.22
, pp. 327-358
-
-
Lonning, P.E.1
Lien, E.A.2
Lundgren, S.3
Kvinnsland, S.4
-
17
-
-
60749093747
-
Pharmacogenetics of tamoxifen: Who should undergo CYP2D6 genetic testing?
-
1:CAS:528:DC%2BD1MXjs1Oktbk%3D This is a concise review of pharmacogenetics of tamoxifen and guidelines for CYP2D6 testing
-
MJ Higgins JM Rae DA Flockhart, et al. 2009 Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Canc Network 7 203 213 1:CAS:528:DC%2BD1MXjs1Oktbk%3D This is a concise review of pharmacogenetics of tamoxifen and guidelines for CYP2D6 testing
-
(2009)
J Natl Compr Canc Network
, vol.7
, pp. 203-213
-
-
Higgins, M.J.1
Rae, J.M.2
Flockhart, D.A.3
-
18
-
-
57049117843
-
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
-
DOI 10.1017/S1462399408000896, PII S1462399408000896
-
V Stearns 2008 Rae JM: Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med 10 e34 10.1017/S1462399408000896 19019258 (Pubitemid 352754676)
-
(2008)
Expert Reviews in Molecular Medicine
, vol.10
, Issue.34
, pp. 1-13
-
-
Stearns, V.1
Rae, J.M.2
-
19
-
-
33745347897
-
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment
-
DOI 10.1016/j.clpt.2006.03.013, PII S0009923606001366
-
S Borges Z Desta L Li, et al. 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 61 74 10.1016/j.clpt.2006.03.013 1:CAS:528:DC%2BD28Xms1enu7k%3D 16815318 (Pubitemid 43946844)
-
(2006)
Clinical Pharmacology and Therapeutics
, vol.80
, Issue.1
, pp. 61-74
-
-
Borges, S.1
Desta, Z.2
Li, L.3
Skaar, T.C.4
Ward, B.A.5
Nguyen, A.6
Jin, Y.7
Storniolo, A.M.8
Nikoloff, D.M.9
Wu, L.10
Hillman, G.11
Hayes, D.F.12
Stearns, V.13
Flockhart, D.A.14
-
20
-
-
33644639136
-
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
-
10.1200/JCO.2005.03.3266 1:CAS:528:DC%2BD28Xnt1ynuw%3D%3D 16361630
-
MP Goetz JM Rae VJ Suman, et al. 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312 9328 10.1200/JCO.2005.03.3266 1:CAS:528: DC%2BD28Xnt1ynuw%3D%3D 16361630
-
(2005)
J Clin Oncol
, vol.23
, pp. 9312-9328
-
-
Goetz, M.P.1
Rae, J.M.2
Suman, V.J.3
-
21
-
-
21344467511
-
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
-
DOI 10.1007/s10549-004-7751-x
-
SA Nowell J Ahn JM Rae, et al. 2005 Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 249 258 10.1007/s10549-004-7751-x 1:CAS:528:DC%2BD2MXltFGqsLs%3D 15952058 (Pubitemid 40903087)
-
(2005)
Breast Cancer Research and Treatment
, vol.91
, Issue.3
, pp. 249-258
-
-
Nowell, S.A.1
Ahn, J.2
Rae, J.M.3
Scheys, J.O.4
Trovato, A.5
Sweeney, C.6
MacLeod, S.L.7
Kadlubar, F.F.8
Ambrosone, C.B.9
-
22
-
-
29144491089
-
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
-
10.1186/bcr993
-
P Wegman L Vainikka O Stål, et al. 2005 Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 284 290 10.1186/bcr993
-
(2005)
Breast Cancer Res
, vol.7
, pp. 284-290
-
-
Wegman, P.1
Vainikka, L.2
Stål, O.3
-
23
-
-
33847034287
-
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
-
DOI 10.1007/s10549-006-9428-0
-
MP Goetz SK Knox VJ Suman, et al. 2007 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 113 121 10.1007/s10549-006-9428-0 1:CAS:528:DC%2BD2sXisVylsg%3D%3D 17115111 (Pubitemid 47555336)
-
(2007)
Breast Cancer Research and Treatment
, vol.101
, Issue.1
, pp. 113-121
-
-
Goetz, M.P.1
Knox, S.K.2
Suman, V.J.3
Rae, J.M.4
Safgren, S.L.5
Ames, M.M.6
Visscher, D.W.7
Reynolds, C.8
Couch, F.J.9
Lingle, W.L.10
Weinshilboum, R.M.11
Fritcher, E.G.B.12
Nibbe, A.M.13
Desta, Z.14
Nguyen, A.15
Flockhart, D.A.16
Perez, E.A.17
Ingle, J.N.18
-
24
-
-
33745926220
-
Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52
-
DOI 10.1007/s10549-005-9152-1
-
JN Ingle VJ Suman JA Mailliard, et al. 2006 Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52 Breast Cancer Res Treat 98 217 222 10.1007/s10549-005-9152-1 1:CAS:528:DC%2BD28XmvVarsr8%3D 16538529 (Pubitemid 44050772)
-
(2006)
Breast Cancer Research and Treatment
, vol.98
, Issue.2
, pp. 217-222
-
-
Ingle, J.N.1
Suman, V.J.2
Mailliard, J.A.3
Kugler, J.W.4
Krook, J.E.5
Michalak, J.C.6
Pisansky, T.M.7
Wold, L.E.8
Donohue, J.H.9
Goetz, M.P.10
Perez, E.A.11
-
25
-
-
34248208754
-
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
-
P Wegman S Elingarami J Carstensen, et al. 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 R7
-
(2007)
Breast Cancer Res
, vol.9
-
-
Wegman, P.1
Elingarami, S.2
Carstensen, J.3
-
26
-
-
43649090742
-
Impact of CYP2D6 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
-
DOI 10.1111/j.1349-7006.2008.00780.x
-
K Kiyotani T Mushiroda M Sasa, et al. 2008 Impact of CYP2D6 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy Cancer Sci 99 995 999 10.1111/j.1349-7006.2008.00780.x 1:CAS:528:DC%2BD1cXlslCrtrc%3D 18294285 (Pubitemid 351997603)
-
(2008)
Cancer Science
, vol.99
, Issue.5
, pp. 995-999
-
-
Kiyotani, K.1
Mushiroda, T.2
Sasa, M.3
Bando, Y.4
Sumitomo, I.5
Hosono, N.6
Kubo, M.7
Nakamura, Y.8
Zembutsu, H.9
-
27
-
-
34548532227
-
Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer
-
DOI 10.1200/JCO.2007.11.4850
-
HS Lim H Ju Lee K Seok Lee, et al. 2007 Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer J Clin Oncol 25 3837 3845 10.1200/JCO.2007.11.4850 1:CAS:528:DC%2BD2sXhtFanu7zK 17761971 (Pubitemid 47477258)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.25
, pp. 3837-3845
-
-
Lim, H.-S.1
Lee, H.J.2
Lee, K.S.3
Lee, E.S.4
Jang, I.-J.5
Ro, J.6
-
28
-
-
36349024762
-
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
-
DOI 10.1200/JCO.2007.12.2705
-
W Schroth L Antoniadou P Fritz, et al. 2007 Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 5187 5193 10.1200/JCO.2007.12.2705 1:CAS:528:DC%2BD2sXhsVKnsbzN 18024866 (Pubitemid 350232249)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.33
, pp. 5187-5193
-
-
Schroth, W.1
Antoniadou, L.2
Fritz, P.3
Schwab, M.4
Muerdter, T.5
Zanger, U.M.6
Simon, W.7
Eichelbaum, M.8
Brauch, H.9
-
29
-
-
72449150287
-
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
-
Ramón Y, Cajal T, Altés A, et al.: Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010, 119:33-38.
-
(2010)
Breast Cancer Res Treat
, vol.119
, pp. 33-38
-
-
Ramón, Y.1
Cajal, T.2
Altés, A.3
-
30
-
-
47749105202
-
Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment
-
10.1093/annonc/mdn155 1:STN:280:DC%2BD1cvotVKmsA%3D%3D 18407954
-
Y Xu Y Sun L Yao, et al. 2008 Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann Oncol 19 1423 1429 10.1093/annonc/mdn155 1:STN:280:DC%2BD1cvotVKmsA%3D%3D 18407954
-
(2008)
Ann Oncol
, vol.19
, pp. 1423-1429
-
-
Xu, Y.1
Sun, Y.2
Yao, L.3
-
31
-
-
70349328422
-
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications
-
10.1158/1055-9965.EPI-09-0516 1:CAS:528:DC%2BD1MXhtFWltb7N 19690182
-
TP Ahern L Pedersen DP Cronin-Fenton, et al. 2009 No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications Cancer Epidemiol Biomarkers Prev 18 2562 2564 10.1158/1055-9965.EPI- 09-0516 1:CAS:528:DC%2BD1MXhtFWltb7N 19690182
-
(2009)
Cancer Epidemiol Biomarkers Prev
, vol.18
, pp. 2562-2564
-
-
Ahern, T.P.1
Pedersen, L.2
Cronin-Fenton, D.P.3
-
32
-
-
61449171134
-
Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
-
Okishiro M, Taguchi T, Jin Kim S, et al.: Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009, 115:952-961.
-
(2009)
Cancer
, vol.115
, pp. 952-961
-
-
Okishiro, M.1
Taguchi, T.2
Jin Kim, S.3
-
33
-
-
67651177578
-
Genotype-guided tamoxifen therapy: Time to pause for reflection?
-
This is a recent review that evaluates the various studies assessing the relationship between CYP2D6 genotypes and breast cancer outcomes. It also highlights potential reasons for heterogeneity in the literature.
-
Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S: Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009, 10:825-833. This is a recent review that evaluates the various studies assessing the relationship between CYP2D6 genotypes and breast cancer outcomes. It also highlights potential reasons for heterogeneity in the literature.
-
(2009)
Lancet Oncol
, vol.10
, pp. 825-833
-
-
Lash, T.L.1
Lien, E.A.2
Sørensen, H.T.3
Hamilton-Dutoit, S.4
-
34
-
-
74549184178
-
Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors
-
abstract CRA508
-
Aubert RE, Stanek EJ, Yao J, et al.: Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 2009, 27(Suppl 18):abstract CRA508.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL. 18
-
-
Aubert, R.E.1
Stanek, E.J.2
Yao, J.3
-
35
-
-
74549167253
-
Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study
-
abstract CRA509
-
Dezentje V, Van Blijderveen NJ, Gelderblom H, et al.: Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study. J Clin Oncol 2009, 27(Suppl 18):abstract CRA509.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL. 18
-
-
Dezentje, V.1
Van Blijderveen, N.J.2
Gelderblom, H.3
-
36
-
-
70349929431
-
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
-
This is a recent large study evaluating the association between CYP2D6 genotypes and breast cancer outcomes.
-
Schroth W, Goetz MP, Hamann U, et al.: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302:1429-1436. This is a recent large study evaluating the association between CYP2D6 genotypes and breast cancer outcomes.
-
(2009)
JAMA
, vol.302
, pp. 1429-1436
-
-
Schroth, W.1
Goetz, M.P.2
Hamann, U.3
-
37
-
-
53249086540
-
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients
-
10.1158/1078-0432.CCR-07-5235 1:CAS:528:DC%2BD1cXhtFaitrjF 18794105
-
WG Newman KD Hadfield A Latif, et al. 2008 Impaired tamoxifen metabolism reduces survival in familial breast cancer patients Clin Cancer Res 14 5913 5918 10.1158/1078-0432.CCR-07-5235 1:CAS:528:DC%2BD1cXhtFaitrjF 18794105
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5913-5918
-
-
Newman, W.G.1
Hadfield, K.D.2
Latif, A.3
-
38
-
-
33747045564
-
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: Data from the Italian tamoxifen trial [1]
-
DOI 10.1200/JCO.2006.06.8072
-
B Bonanni D Macis P Maisonneuve, et al. 2006 Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial J Clin Oncol 24 3708 3709 10.1200/JCO.2006.06. 8072 16877740 (Pubitemid 46630548)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.22
, pp. 3708-3709
-
-
Bonanni, B.1
Macis, D.2
Maisonneuve, P.3
Johansson, H.A.4
Gucciardo, G.5
Oliviero, P.6
Travaglini, R.7
Muraca, M.G.8
Rotmensz, N.9
Veronesi, U.10
Decensi, A.U.11
-
39
-
-
10444221019
-
Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients
-
DOI 10.1016/j.canlet.2004.08.027, PII S0304383504006792
-
AN Tucker KA Tkaczuk LM Lewis, et al. 2005 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients Cancer Lett 217 61 72 10.1016/j.canlet.2004.08.027 1:CAS:528:DC%2BD2cXhtVKksbfL 15596297 (Pubitemid 39642867)
-
(2005)
Cancer Letters
, vol.217
, Issue.1
, pp. 61-72
-
-
Tucker, A.N.1
Tkaczuk, K.A.2
Lewis, L.M.3
Tomic, D.4
Lim, C.K.5
Flaws, J.A.6
-
40
-
-
70349575970
-
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Consortium on Breast Cancer Pharmacogenomics Investigators
-
Lynn Henry N, Rae JM, Li L, et al.: Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Consortium on Breast Cancer Pharmacogenomics Investigators. Breast Cancer Res Treat 2009, 117:571-575.
-
(2009)
Breast Cancer Res Treat
, vol.117
, pp. 571-575
-
-
Lynn Henry, N.1
Rae, J.M.2
Li, L.3
-
41
-
-
67849116739
-
COBRA investigators: Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
-
10.1038/tpj.2009.14 1:CAS:528:DC%2BD1MXlsVKksbw%3D 19421167
-
JM Rae MJ Sikora NL Henry, et al. 2009 COBRA investigators: Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients Pharmacogenomics J 9 258 264 10.1038/tpj.2009.14 1:CAS:528: DC%2BD1MXlsVKksbw%3D 19421167
-
(2009)
Pharmacogenomics J
, vol.9
, pp. 258-264
-
-
Rae, J.M.1
Sikora, M.J.2
Henry, N.L.3
-
42
-
-
58049217574
-
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy
-
10.1200/JCO.2008.16.8377 19018086
-
YT Jin DF Hayes L Li, et al. 2008 Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy J Clin Oncol 26 5849 5854 10.1200/JCO.2008.16.8377 19018086
-
(2008)
J Clin Oncol
, vol.26
, pp. 5849-5854
-
-
Jin, Y.T.1
Hayes, D.F.2
Li, L.3
-
43
-
-
0142181118
-
Anastrozole Alone or in Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early-Stage Breast Cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial Efficacy and Safety Update Analyses
-
DOI 10.1002/cncr.11745
-
M Baum A Buzdar J Cuzick, et al. 2003 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 1802 1810 10.1002/cncr.11745 1:CAS:528:DC%2BD3sXpt1arsbc%3D 14584060 (Pubitemid 37310221)
-
(2003)
Cancer
, vol.98
, Issue.9
, pp. 1802-1810
-
-
Baum, M.1
Buzdar, A.2
Cuzick, J.3
Forbes, J.4
Houghton, J.5
Howell, A.6
Sahmoud, T.7
-
44
-
-
33645729721
-
NCCN task force report: Adjuvant therapy for breast cancer
-
RW Carlson E Brown HJ Burstein, et al. 2006 NCCN Task Force Report: Adjuvant therapy for breast cancer J Natl Compr Canc Netw 4 Suppl 1 S1 S26
-
(2006)
J Natl Compr Canc Netw
, vol.4
, Issue.SUPPL. 1
-
-
Carlson, R.W.1
Brown, E.2
Burstein, H.J.3
-
45
-
-
20044382779
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004
-
DOI 10.1200/JCO.2005.09.121
-
EP Winer C Hudis HJ Burstein, et al. 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 J Clin Oncol 23 619 629 10.1200/JCO.2005.09.121 1:CAS:528:DC%2BD2MXitVartb4%3D 15545664 (Pubitemid 46224240)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.3
, pp. 619-629
-
-
Winer, E.P.1
Hudis, C.2
Burstein, H.J.3
Wolff, A.C.4
Pritchard, K.I.5
Ingle, J.N.6
Chlebowski, R.T.7
Gelber, R.8
Edge, S.B.9
Gralow, J.10
Cobleigh, M.A.11
Mamounas, E.P.12
Goldstein, L.J.13
Whelan, T.J.14
Powles, T.J.15
Bryant, J.16
Perkins, C.17
Perotti, J.18
Braun, S.19
Langer, A.S.20
Browman, G.P.21
Somerfield, M.R.22
more..
-
46
-
-
44049098379
-
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis
-
This study used a Markov model to identify a subpopulation of postmenopausal women who could benefit more from tamoxifen than aromatase inhibitors based on CDYP2D6 status.
-
• Punglia RS, Burstein HJ, Winer EP, Weeks JC: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008, 100:642-648. This study used a Markov model to identify a subpopulation of postmenopausal women who could benefit more from tamoxifen than aromatase inhibitors based on CDYP2D6 status.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 642-648
-
-
Punglia, R.S.1
Burstein, H.J.2
Winer, E.P.3
Weeks, J.C.4
-
47
-
-
44049098957
-
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
-
10.1093/jnci/djn127 18445818
-
DF Hayes V Stearns J Rae, et al. 2008 A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst 100 610 613 10.1093/jnci/djn127 18445818
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 610-613
-
-
Hayes, D.F.1
Stearns, V.2
Rae, J.3
-
48
-
-
53249140840
-
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: Combining inherited and tumor gene markers for prediction of tamoxifen resistance
-
10.1158/1078-0432.CCR-08-0619 1:CAS:528:DC%2BD1cXhtFaitrjO 18794098
-
MP Goetz VJ Suman FJ Couch, et al. 2008 Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance Clin Cancer Res 14 5864 5868 10.1158/1078-0432.CCR-08-0619 1:CAS:528:DC%2BD1cXhtFaitrjO 18794098
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5864-5868
-
-
Goetz, M.P.1
Suman, V.J.2
Couch, F.J.3
-
49
-
-
38949105895
-
A single-nucleotide polymorphismin the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma
-
DOI 10.1158/1078-0432.CCR-07-1923
-
R Colomer M Monzo I Tusquets, et al. 2008 A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma Clin Cancer Res 14 811 816 10.1158/1078-0432.CCR-07-1923 1:CAS:528:DC%2BD1cXhsFykt7g%3D 18245543 (Pubitemid 351231164)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.3
, pp. 811-816
-
-
Colomer, R.1
Monzo, M.2
Tusquets, I.3
Rifa, J.4
Baena, J.M.5
Barnadas, A.6
Calvo, L.7
Carabantes, F.8
Crespo, C.9
Munoz, M.10
Llombart, A.11
Plazaola, A.12
Artells, R.13
Gilabert, M.14
Lloveras, B.15
Alba, E.16
-
50
-
-
58849087666
-
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer
-
10.1158/1078-0432.CCR-08-2006 19118028
-
VO Dezentjé HJ Guchelaar JW Nortier, et al. 2009 Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer Clin Cancer Res 15 15 21 10.1158/1078-0432.CCR-08-2006 19118028
-
(2009)
Clin Cancer Res
, vol.15
, pp. 15-21
-
-
Dezentjé, V.O.1
Guchelaar, H.J.2
Nortier, J.W.3
-
51
-
-
67749114265
-
CYP2D6 and tamoxifen: DNA matters in breast cancer
-
This is a recent review on the current role of pharmacogenetics of tamoxifen in clinical practice
-
• Hoskins JM, Carey LA, McLeod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009, 9:576-586. This is a recent review on the current role of pharmacogenetics of tamoxifen in clinical practice.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 576-586
-
-
Hoskins, J.M.1
Carey, L.A.2
McLeod, H.L.3
|